Berenberg analyst Xian Deng initiates coverage on Genmab (NASDAQ:GMAB) with a Sell rating.
Berenberg Initiates Coverage On Genmab with Sell Rating
Berenberg analyst Xian Deng initiates coverage on Genmab (NASDAQ:GMAB) with a Sell rating.
Related Posts
Zai Lab Q1 EPS $(0.86) Beats $(1.20) Estimate, Sales $46.72M Beat $45.72M Estimate
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.20) by 28.33 percent. This is a 67.42 percent increase over losses of $(2.64) per share from the same
Keefe, Bruyette & Woods Upgrades New York Mortgage Trust to Outperform, Announces $4.5 Price Target
Keefe, Bruyette & Woods analyst Bose George upgrades New York Mortgage Trust (NASDAQ:NYMT) from Market Perform to Outperform and announces $4.5 price target.
REE Automotive Receives $17M Funding From UK Government
REE Automotive Ltd’s (NASDAQ:REE) REEcorner technology was awarded $17 million in funding from the UK government. This funding is part of…